News and Announcements
Aeeris Quarterly Report for Q1 Ended 30 September 2016
- Published November 03, 2016 3:47PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
31st October 2016, ASX Announcement
Financial Highlights
- Total cash receipts of $270,205
- Receipt of $589,057 cash R&D Tax Rebate since the end of the Reporting Quarter, received on 14 October 2016
- Cash position at date of this Announcement of $1.519 million (unaudited)
- Net decrease in cash held during the Reporting Quarter of $625,170, compared with $429,971 in the previous quarter
- Cash position at end of quarter (30 th September 2016) of $1.11 million (unaudited)
Business Highlights
- Much activity during the reported Quarter was focused on technology R&D and software development attached to some major new business opportunities. Delays in this production process stalled new revenues from other sources. This factor, combined with the decision not to renew the Brisbane City Council service, has impacted revenues for the Quarter.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
